Simoctocog alfa for the treatment of hemophilia A

References

• Mariani G, Di Paolantonio T, Baklaya R, et al. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The ad hoc study group of the fondazione dell’Emofilia. Transfusion. 1993;33:814–818.
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Brown DL, Hoots K, et al. Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia. 2004;10(Suppl 4):205–210.
   PubMed Web of Science ®Google Scholar
• Morfini M, Mannucci PM, Ciavarella N, et al. Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang. 1994;67:178–182.
   PubMed Web of Science ®Google Scholar
• Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med. 1994;120:1–7.
   PubMed Web of Science ®Google Scholar
• Morfini M, Azzi A, Mannucci PM. B19 parvovirus withstands “super heating” in antihemophilic concentrates. Thromb Haemost. 1996;76:821.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mannucci PM, Gringeri A, et al. Eliminating parvovirus B19 from blood products. Lancet. 1994;343:798.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion. 1997;37:517–522.
   PubMed Web of Science ®Google Scholar
• Soucie JM, De Staercke C, Monahan PE, et al. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Transfusion. 2013;53:1217–1225.
   PubMed Web of Science ®Google Scholar
• Soucie JM, Monahan PE, Kulkarni R, et al. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates. Transfusion. 2013;53:1143–1144.
   PubMed Web of Science ®Google Scholar
• Schneider B, Fryer JF, Oldenburg J, et al. Frequency of contamination of coagulation factor concentrates with novel human parvovirus PARV4. Haemophilia. 2008;14:978–986.
   PubMed Web of Science ®Google Scholar
• Sharp CP, Lail A, Donfield S, et al. Virologic and clinical features of primary infection with human parvovirus 4 in subjects with hemophilia: frequent transmission by virally inactivated clotting factor concentrates. Transfusion. 2012;52:1482–1489.
   PubMed Web of Science ®Google Scholar
• Fryer JF, Hubbard AR, Baylis SA. Human parvovirus PARV4 in clotting factor VIII concentrates. Vox Sang. 2007;93:341–347.
   PubMed Web of Science ®Google Scholar
• Brackmann HH, Aygören E, Scharrer I, et al. Two years’ experience with two recombinant factor VIII concentrates. Blood Coagul Fibrinolysis. 1993;4:421–424.
   PubMed Web of Science ®Google Scholar
• Bray GL, Gomperts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428–2435.
   PubMed Web of Science ®Google Scholar
• Medical and Scientific Advisory Council. MASAC Recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Concerning-Products-Licensed-for-the-Treatment-of-Hemophilia-and-Other-Bleeding-Disorders. cited 2017 Sep 18
   Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:1–47.
   PubMed Web of Science ®Google Scholar
• Richards M, Williams M, Chalmers E, et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the BRITISH COMMITTEE for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149:498–507.
   PubMed Web of Science ®Google Scholar
• Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007;13:606–612.
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418–435.
   PubMed Web of Science ®Google Scholar
• De Biasi R, Rocino A, Papa ML, et al. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;71:544–547.
   PubMed Web of Science ®Google Scholar
• Kreuz W, Ettingshausen CE, Zyschka A, et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. Semin Thromb Hemost. 2002;28:285–290.
   PubMed Web of Science ®Google Scholar
• Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992;339:594–598.
   PubMed Web of Science ®Google Scholar
• Lusher JM. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development. Semin Thromb Hemost. 2002;28:273–276.
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124:3398–3408.
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064.
   PubMed Web of Science ®Google Scholar
• Messori A, Longo G, Morfini M, et al. Individualization of factor VIII dosage. J Clin Hosp Pharm. 1984;9:95–103.
   PubMedGoogle Scholar
• Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia. 2016;22:487–498.
   PubMed Web of Science ®Google Scholar
• Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20:607–615.
   PubMed Web of Science ®Google Scholar
• White GC 2nd. Summary of clinical experience with recombinant factor VIII products-Recombinate. Ann Hematol. 1994;68(Suppl 3):S7–8.
   PubMed Web of Science ®Google Scholar
• Rothschild C, Laurian Y, Satre EP, et al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost. 1998;80:779–783.
   PubMed Web of Science ®Google Scholar
• Aygören-Pürsün E, Scharrer I. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost. 1997;78:1352–1356.
   PubMed Web of Science ®Google Scholar
• Casademunt E, Martinelle K, Jernberg M, et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur J Haematol. 2012;89:165–176.
   PubMed Web of Science ®Google Scholar
• Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017;8:67–73.
   PubMed Web of Science ®Google Scholar
• Agersø H, Stennicke HR, Pelzer H, et al. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs. Haemophilia. 2012;18:941–947.
   PubMed Web of Science ®Google Scholar
• Turecek PL, Bossard MJ, Graninger M, et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation. Hamostaseologie. 2012;32(Suppl 1):S29–38.
   PubMed Web of Science ®Google Scholar
• Gu JM, Ramsey P, Evans V, et al. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94–9027) for haemophilia A. Haemophilia. 2014;20:593–600.
   PubMed Web of Science ®Google Scholar
• Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94–9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014;12:488–496.
   PubMed Web of Science ®Google Scholar
• Wynn TT, Gumuscu B. Potential role of a new PEGylated recombinant factor VIII for hemophilia A. J Blood Med. 2016;7:121–128.
   PubMed Web of Science ®Google Scholar
• Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood. 2012;119:3031–3037.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123:317–325.
   PubMed Web of Science ®Google Scholar
• Schmidbauer S, Witzel R, Robbel L, et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2015;136:388–395.
   PubMed Web of Science ®Google Scholar
• Zollner SB, Raquet E, Müller-Cohrs J, et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res. 2013;132:280–287.
   PubMed Web of Science ®Google Scholar
• Klamroth R, Simpson M, Von Depka-Prondzinski M, et al. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A. Haemophilia. 2016;22:730–738.
   PubMed Web of Science ®Google Scholar
• Collins PW, Møss J, Knobe K, et al. Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost. 2012;10:2305–2312.
   PubMed Web of Science ®Google Scholar
• Negrier C, Young G, Abdul Karim F, et al. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 2016;22:507–513.
   PubMed Web of Science ®Google Scholar
• Schulte S. Half-life extension through albumin fusion technologies. Thromb Res. 2009;124(Suppl 2):S6–8.
   PubMed Web of Science ®Google Scholar
• Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120:2405–2411.
   PubMed Web of Science ®Google Scholar
• Morfini M. Pharmacokinetic drug evaluation of albutrepenonacog alfa (CSL654) for the treatment of hemophilia. Expert Opin Drug Metab Toxicol. 2016;12:1359–1365.
   PubMed Web of Science ®Google Scholar
• Peters RT, Low SC, Kamphaus GD, et al. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood. 2010;115:2057–2064.
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood. 2012;119:666–672.
   PubMed Web of Science ®Google Scholar
• Morfini M, Zanon E. Emerging drugs for the treatment of hemophilia A and B. Expert Opin Emerg Drugs. 2016;21:301–313.
   PubMed Web of Science ®Google Scholar
• Sandberg H, Kannicht C, Stenlund P, et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res. 2012;130:808–817.
   PubMed Web of Science ®Google Scholar
• Kannicht C, Ramström M, Kohla G, et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res. 2013;131:78–88.
   PubMed Web of Science ®Google Scholar
• Kannicht C, Kohla G, Tiemeyer M, et al. A new recombinant factor VIII: from genetics to clinical use. Drug Des Devel Ther. 2015;9:3817–3819.
   PubMed Web of Science ®Google Scholar
• Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III. Ann Hematol. 1992;65:253–259.
   PubMed Web of Science ®Google Scholar
• Morfini M, Mannucci PM, Tenconi PM, et al. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost. 1993;70:270–272.
   PubMed Web of Science ®Google Scholar
• Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood. 2007;109:610–612.
   PubMed Web of Science ®Google Scholar
• Delignat S, Repessé Y, Navarrete AM, et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia. 2012;18:248–254.
   PubMed Web of Science ®Google Scholar
• Lenting PJ, Neels JG, Van Den Berg BM, et al. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein. J Biol Chem. 1999;274:23734–23739.
   PubMed Web of Science ®Google Scholar
• Saenko EL, Yakhyaev AV, Mikhailenko I, et al. Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism. J Biol Chem. 1999;274:37685–37692.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Negrier C, Kohla G, et al. The first recombinant FVIII produced in human cells – an update on its clinical development programme. Haemophilia. 2014;20(Suppl 1):1–9.
   PubMed Web of Science ®Google Scholar
• Tiede A, Oldenburg J, Lissitchkov T, et al. Prophylaxis vs. on-demand treatment with Nuwiq® (Human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 2016;22:374–380.
   PubMed Web of Science ®Google Scholar
• Klukowska A, Szczepański T, Vdovin V, et al. Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics. Haemophilia. 2016;22:232–239.
   PubMed Web of Science ®Google Scholar
• Lissitchkov T, Hampton K, Von Depka M, et al. Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety. Haemophilia. 2016;22:225–231.
   PubMed Web of Science ®Google Scholar
• Franchini M, Mannucci PM. Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). Expert Opin Drug Saf. 2017;16:405–410.
   PubMed Web of Science ®Google Scholar
• Kessler C, Oldenburg J, Ettingshausen CE, et al. Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014. Haemophilia. 2015;21(Suppl 1):1–12.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Nuwiq® European Public Assessment report (EPAR). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002813/WC500179342.pdf cited 2017 Sep 18
   Google Scholar
• Lissitchkov T, Rusen L, Georgiev P, et al. PK-guided personalized prophylaxis with Nuwiq® (human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia. 2017. E-pub ahead of print. DOI:10.1111/hae.13251.
   Web of Science ®Google Scholar
• Liesner R, Abashidze M, Aleinikova O, et al. Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A – Interim results from the NuProtect Study. Haemophilia. 2017. E-pub ahead of print. DOI:10.1111/hae.13320.
   Google Scholar
• Ruffo S, Messori A, Grasela TH, et al. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput Programs Biomed. 1985;19:167–177.
   PubMedGoogle Scholar
• Carlsson M, Berntorp E, Björkman S, et al. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia. 1997;3:96–101.
   PubMed Web of Science ®Google Scholar
• Carlsson M, Björkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia. 1998;4:83–88.
   PubMed Web of Science ®Google Scholar
• Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost. 1991;66:384–386.
   PubMed Web of Science ®Google Scholar
• Lee M, Morfini M, Schulman S, Ingerslev J. And the Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and standardization committee communication the design and analysis of pharmacokinetic studies of coagulation factors. Posted on ISTH. 21 March 2001:https://c.ymcdn.com/sites/www.isth.org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf? cited 2017 Sep 18
   Google Scholar
• Food and Drug Administration. Guidance for industry. Exposure-response relationships – study design, data analysis, and regulatory applications. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf. cited 2017 Sept 18
   Google Scholar
• European Medicines Agency. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003029.pdf. cited 2017 Sept 18
   Google Scholar
• Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia. 2007;13:2–8.
   PubMed Web of Science ®Google Scholar
• Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–275.
   PubMed Web of Science ®Google Scholar
• Valentino LA, Pipe SW, Collins PW, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016;22:514–520.
   PubMed Web of Science ®Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–723.
   Web of Science ®Google Scholar
• Morfini M, Fagnani S, Borchiellini A et al. NuPreviq: long-term program of treatment personalization and support for patients and clinicians. Poster presented at World Federation of Hemophilia Congress, 24–28 July 2016, P-W-150.
   Google Scholar
• Gouw SC, Van Der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368:231–239.
   PubMed Web of Science ®Google Scholar
• Fischer K, Iorio A, Hollingsworth R, et al. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia. 2016;22:36–38.
   PubMed Web of Science ®Google Scholar
• Todd JL, Palmer SM. Danger signals in regulating the immune response to solid organ transplantation. J Clin Invest. 2017;127:2464–2472.
   PubMed Web of Science ®Google Scholar
• Raymond SL, Holden DC, Mira JC, et al. Microbial recognition and danger signals in sepsis and trauma. Biochim Biophys Acta. 2017; pii: S0925–4439(17) 30026–1.
   PubMedGoogle Scholar